Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques.

ABSTRACT: Treatment nonadherence is a pressing issue in people living with HIV (PLWH), as they require lifelong therapy to maintain viral suppression. Poor adherence leads to antiretroviral (ARV) resistance, transmission to others, AIDS progression, and increased morbidity and mortality. Long-acting (LA) ARV therapy is a promising strategy to combat the clinical drawback of user-dependent dosing. Islatravir (ISL) is a promising candidate for HIV treatment given its long half-life and high potency. Here we show constant ISL release from a subdermal LA nanofluidic implant achieves viral load reduction in SHIV-infected macaques. Specifically, a mean delivery dosage of 0.21 ± 0.07 mg/kg/day yielded a mean viral load reduction of -2.30 ± 0.53 log₁₀ copies/mL at week 2, compared to baseline. Th

SUBMITTER: Pons-Faudoa FP 

PROVIDER: S-EPMC10922355 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature